Development of Small Molecule Inhibitor Targeting Aminoacyl-Trna Synthetase Interacting Multifunctional Protein 2 (AIMP2)-DX2 As Anti-Cancer Therapeutics Volume 3 - Issue 5

Seungbeom Lee*

• Department of Chemistry and Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, United States

Received: December 17, 2020;   Published: February 19, 2021

Corresponding author: Seungbeom Lee, Department of Chemistry and Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, United States

DOI: 10.32474/DDIPIJ.2021.03.000172

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Recently, noncanonical roles of Multi-tRNA Synthetase Complex (MSC) proteins including Aminoacyl-tRNA synthetase Interacting Multifunctional Proteins (AIMPs) have been revealed and served as a chance to develop novel therapeutics with their unique mechanisms. The disease specific splicing variant of AIMP2 (AIMP2-DX2) has recently been considered a novel promising therapeutic target in several cancers. However, few studies on developing small molecule inhibitors of AIMP2-DX2 have been reported. In this paper, the brief summary for AIMP2-DX2 as a medicinal chemistry target, has been demonstrated.

Keywords: Drug Discovery; Medicinal Chemistry; AIMP2-DX2; Anti-cancer; Alternative Splicing Variant

Abstract| Mini Review| References|